Sinopharm Capital chipped in for a series B round aimed at expanding MEDx's precision healthcare operation.
Singapore-based precision medicine developer MEDx Translational Medicine has closed a RMB350m ($51.4m) series B round involving Sinopharm Capital, a subsidiary of pharmaceutical firm Sinopharm.
The round was led by Qiming Venture Partners and was rounded off by Tsing Song Capital, Broad Resources, Quan Capital and Angel Investment.
Founded in 2013, MEDx is a precision healthcare company focused on delivering medicine and diagnostic tests driven by biomarkers identified from its genetics-based discovery system.
The series B capital will go to its…
